Female-pattern hair loss: therapeutic update

Ramos, Paulo Müller; Fernandes, Daniel; Radwanski, Henrique; Almeida, Rita Fernanda Cortez de; Miot, Hélio Amante

doi:10.1016/j.abd.2022.09.006

Cited by 8 publications

(2 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hair loss may also be one of the signs of androgen excess in women, along with hirsutism and acne. FPHL affects the central parietal part of the scalp [ 28 ]. In most cases, it is connected with polycystic ovary syndrome (PCOS) [ 29 ].…”

Section: Androgensmentioning

confidence: 99%

The Hormonal Background of Hair Loss in Non-Scarring Alopecias

Owecka,

Tomaszewska,

Dobrzeniecki

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Hair loss is a common clinical condition connected with serious psychological distress and reduced quality of life. Hormones play an essential role in the regulation of the hair growth cycle. This review focuses on the hormonal background of hair loss, including pathophysiology, underlying endocrine disorders, and possible treatment options for alopecia. In particular, the role of androgens, including dihydrotestosterone (DHT), testosterone (T), androstenedione (A4), dehydroepiandrosterone (DHEA), and its sulfate (DHEAS), has been studied in the context of androgenetic alopecia. Androgen excess may cause miniaturization of hair follicles (HFs) in the scalp. Moreover, hair loss may occur in the case of estrogen deficiency, appearing naturally during menopause. Also, thyroid hormones and thyroid dysfunctions are linked with the most common types of alopecia, including telogen effluvium (TE), alopecia areata (AA), and androgenetic alopecia. Particular emphasis is placed on the role of the hypothalamic–pituitary–adrenal axis hormones (corticotropin-releasing hormone, adrenocorticotropic hormone (ACTH), cortisol) in stress-induced alopecia. This article also briefly discusses hormonal therapies, including 5-alpha-reductase inhibitors (finasteride, dutasteride), spironolactone, bicalutamide, estrogens, and others.

show abstract

Section: Androgensmentioning

confidence: 99%

The Hormonal Background of Hair Loss in Non-Scarring Alopecias

Owecka,

Tomaszewska,

Dobrzeniecki

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Hyperkalemia and menstrual abnormalities are among the possible adverse effects of spironolactone, which suppresses powerful androgens. Hair transplantation, which requires a sufficient amount of donor hair for excellent outcomes, and laser treatment at 660 nm are also other possible choices [18] .…”

Section: Treatment/managementmentioning

confidence: 99%

Relation between Androgenic Alopecia with Metabolic Syndrome: Review Article

2024

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Androgenetic alopecia (AGA) is the most prevalent form of hair loss in men and women, characterized by a progressive thinning of hair influenced by androgens and genetic predisposition. Recent studies suggest a potential link between AGA and metabolic syndrome (MetS), a cluster of conditions that increase the risk for heart disease and other health problems. Understanding the association between AGA and MetS could lead to improved screening and management strategies, potentially mitigating cardiovascular risk in affected individuals. Objective: This review aimed to synthesize current knowledge on the pathophysiology, genetic basis, and treatment options for AGA, with a focus on the relationship between AGA and MetS. The objective was to highlight the importance of early detection and comprehensive management of AGA, considering its association with systemic health issues. Methods: A thorough literature review was conducted, analyzing studies from PubMed, Cochrane Library, and Google Scholar databases. Articles published up to April 2023 were included, with a focus on those providing insights into the pathophysiology of AGA, its treatment, and its association with MetS. Cross-sectional, cohort, and case-control studies were reviewed to assess the strength of the relationship between AGA and MetS. Conclusions: AGA is not only a cosmetic concern but also a potential marker for underlying metabolic dysregulation. The evidence suggested a strong association between AGA and MetS, emphasizing the role of androgens and genetic predisposition in both conditions. Early intervention in patients with AGA could serve as a preventive strategy for MetS and related cardiovascular diseases. Healthcare providers should consider screening for MetS components in patients presenting with AGA, particularly in those with a family history of metabolic or cardiovascular disorders.

show abstract